Capra Biosciences builds a continuous-flow biofilm bioreactor platform aimed at changing the economics of making sustainable petrochemical replacements using biology. Its first product is retinol, a cosmetic ingredient the company produces biologically rather than from fossil fuels. The company plans to build a modular production-scale reactor and extend capabilities to produce aviation and industrial lubricants in future phases. Capra says its platform organism and modular reactors avoid many traditional bioreactor scale-up challenges and allow capacity to grow by adding units. The company emerged from the IndieBio program backed by SOSV and is based in the Prince William Science Accelerator in Manassas, VA. Capra also supports development through a cooperative research and development agreement (CRADA) with the U.S. Naval Research Laboratory.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2022